Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future

Area of Science:

• Cardiology
• Regenerative Medicine
• Cell Biology

Background:

• Heart Failure (HF) prevalence is rising, with ischemic heart failure accounting for 50% of cases, often stemming from Myocardial Infarction (MI).
• Current treatments like reducing cardiac load and revascularization offer partial benefits but fail to fully rescue cardiomyocytes or halt HF progression.
• Mesenchymal Stem Cells (MSCs) demonstrate potential in improving cardiac function and cardiomyocyte survival in MI models and patients.

Purpose of the Study:

• To review the role of Mesenchymal Stem Cells (MSCs) in protecting cardiomyocytes.
• To explore the potential of MSC-derived exosomes as a therapeutic approach for ischemic heart failure.
• To highlight future applications of exosomes in heart failure treatment.

Main Methods:

• Review of existing literature on Mesenchymal Stem Cells (MSCs) and their therapeutic effects in heart failure models.
• Analysis of the paracrine mechanisms of MSCs, focusing on exosomes.
• Examination of studies investigating MSC-derived exosomes for cardiomyocyte protection.

Main Results:

• Mesenchymal Stem Cells (MSCs) administration improves cardiac function and survival of cardiomyocytes post-MI.
• The short in vivo persistence of MSCs suggests their therapeutic benefits are largely mediated by secreted factors, particularly exosomes.
• MSC-derived exosomes exhibit protective effects on cardiomyocytes, indicating their potential as cell-free therapy.

Conclusions:

• MSC-derived exosomes represent a promising cell-free therapeutic strategy for ischemic heart failure.
• Further research into MSC-derived exosomes can facilitate their clinical application in treating heart failure.
• Exosomes offer a viable alternative to cell-based therapies for managing heart failure.